Clinical Trial Update: A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction [Phase 2]

View source ↗

Summary

Phase 2 study evaluating atezolizumab and trastuzumab in combination with capecitabine and oxaliplatin for HER2-positive locally advanced resectable gastroesoph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Eloxatin (oxaliplatin) (oxaliplatin)
• Herceptin (trastuzumab) (trastuzumab)
• Tecentriq (atezolizumab) (atezolizumab)
• Xeloda (capecitabine) (capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-17